O	0	5	Phase
O	6	9	III
O	10	20	randomized
O	21	26	trial
O	27	29	of
B-intervention	30	39	Calendula
I-intervention	40	51	officinalis
O	52	60	compared
O	61	65	with
B-control	66	75	trolamine
O	76	79	for
O	80	83	the
O	84	94	prevention
O	95	97	of
B-condition	98	103	acute
I-condition	104	114	dermatitis
O	115	121	during
O	122	133	irradiation
O	134	137	for
O	138	144	breast
O	145	151	cancer
O	151	152	.

O	153	156	The
O	157	170	effectiveness
O	171	173	of
O	174	184	nonsteroid
O	185	192	topical
O	193	199	agents
O	200	203	for
O	204	207	the
O	208	218	prevention
O	219	221	of
O	222	227	acute
O	228	238	dermatitis
O	239	245	during
O	246	254	adjuvant
O	255	267	radiotherapy
O	268	271	for
O	272	278	breast
O	279	288	carcinoma
O	289	292	has
O	293	296	not
O	297	301	been
O	302	314	demonstrated
O	314	315	.

O	316	319	The
O	320	324	goal
O	325	327	of
O	328	332	this
O	333	338	study
O	339	342	was
O	343	345	to
O	346	353	compare
O	354	357	the
O	358	371	effectiveness
O	372	374	of
O	375	384	calendula
O	385	386	(
O	386	393	Pommade
O	394	396	au
O	397	406	Calendula
O	407	410	par
O	411	420	Digestion
O	420	421	;
O	422	428	Boiron
O	429	432	Ltd
O	432	433	,
O	434	443	Levallois
O	443	444	-
O	444	450	Perret
O	450	451	,
B-location	452	458	France
O	458	459	)
O	460	464	with
O	465	469	that
O	470	472	of
O	473	482	trolamine
O	483	484	(
O	484	491	Biafine
O	491	492	;
O	493	501	Genmedix
O	502	505	Ltd
O	505	506	,
O	507	513	France
O	513	514	)
O	514	515	,
O	516	521	which
O	522	524	is
O	525	535	considered
O	536	538	in
O	539	543	many
O	544	556	institutions
O	557	559	to
O	560	562	be
O	563	566	the
O	567	576	reference
O	577	584	topical
O	585	590	agent
O	590	591	.

O	592	599	Between
O	600	604	July
O	605	609	1999
O	610	613	and
O	614	618	June
O	619	623	2001
O	623	624	,
B-total-participants	625	628	254
B-eligibility	629	637	patients
I-eligibility	638	641	who
I-eligibility	642	645	had
I-eligibility	646	650	been
I-eligibility	651	659	operated
I-eligibility	660	662	on
I-eligibility	663	666	for
I-eligibility	667	673	breast
I-eligibility	674	680	cancer
I-eligibility	681	684	and
I-eligibility	685	688	who
I-eligibility	689	693	were
I-eligibility	694	696	to
I-eligibility	697	704	receive
I-eligibility	705	718	postoperative
I-eligibility	719	728	radiation
I-eligibility	729	736	therapy
O	737	741	were
O	742	750	randomly
O	751	760	allocated
O	761	763	to
O	764	775	application
O	776	778	of
O	779	785	either
O	786	795	trolamine
O	796	797	(
B-control-participants	797	800	128
O	801	809	patients
O	809	810	)
O	811	813	or
O	814	823	calendula
O	824	825	(
B-intervention-participants	825	828	126
O	829	837	patients
O	837	838	)
O	839	841	on
O	842	845	the
O	846	856	irradiated
O	857	863	fields
O	864	869	after
O	870	874	each
O	875	882	session
O	882	883	.

O	884	887	The
O	888	895	primary
O	896	899	end
O	900	905	point
O	906	909	was
O	910	913	the
B-outcome-Measure	914	924	occurrence
I-outcome-Measure	925	927	of
I-outcome-Measure	928	933	acute
I-outcome-Measure	934	944	dermatitis
I-outcome-Measure	945	947	of
I-outcome-Measure	948	953	grade
I-outcome-Measure	954	955	2
I-outcome-Measure	956	958	or
I-outcome-Measure	959	965	higher
O	965	966	.

O	967	977	Prognostic
O	978	985	factors
O	985	986	,
O	987	996	including
O	997	1006	treatment
O	1007	1017	modalities
O	1018	1021	and
O	1022	1029	patient
O	1030	1045	characteristics
O	1045	1046	,
O	1047	1051	were
O	1052	1056	also
O	1057	1069	investigated
O	1069	1070	.

O	1071	1080	Secondary
O	1081	1084	end
O	1085	1091	points
O	1092	1096	were
O	1097	1100	the
B-outcome-Measure	1101	1111	occurrence
I-outcome-Measure	1112	1114	of
I-outcome-Measure	1115	1119	pain
O	1119	1120	,
O	1121	1124	the
B-outcome-Measure	1125	1133	quantity
I-outcome-Measure	1134	1136	of
I-outcome-Measure	1137	1144	topical
I-outcome-Measure	1145	1150	agent
I-outcome-Measure	1151	1155	used
O	1155	1156	,
O	1157	1160	and
B-outcome-Measure	1161	1168	patient
I-outcome-Measure	1169	1181	satisfaction
O	1181	1182	.

O	1183	1186	The
B-outcome	1187	1197	occurrence
I-outcome	1198	1200	of
I-outcome	1201	1206	acute
I-outcome	1207	1217	dermatitis
I-outcome	1218	1220	of
I-outcome	1221	1226	grade
I-outcome	1227	1228	2
I-outcome	1229	1231	or
I-outcome	1232	1238	higher
O	1239	1242	was
O	1243	1256	significantly
O	1257	1262	lower
O	1263	1264	(
B-iv-bin-percent	1264	1266	41
I-iv-bin-percent	1266	1267	%
O	1268	1269	v
B-cv-bin-percent	1270	1272	63
I-cv-bin-percent	1272	1273	%
O	1273	1274	;
O	1275	1276	P
O	1277	1278	<
O	1278	1279	.
O	1279	1282	001
O	1282	1283	)
O	1284	1288	with
O	1289	1292	the
O	1293	1296	use
O	1297	1299	of
O	1300	1309	calendula
O	1310	1314	than
O	1315	1319	with
O	1320	1329	trolamine
O	1329	1330	.

O	1331	1339	Moreover
O	1339	1340	,
O	1341	1349	patients
O	1350	1359	receiving
O	1360	1369	calendula
O	1370	1373	had
O	1374	1378	less
O	1379	1387	frequent
O	1388	1400	interruption
O	1401	1403	of
O	1404	1416	radiotherapy
O	1417	1420	and
O	1421	1434	significantly
O	1435	1442	reduced
B-outcome	1443	1452	radiation
I-outcome	1452	1453	-
I-outcome	1453	1460	induced
I-outcome	1461	1465	pain
O	1465	1466	.

O	1467	1476	Calendula
O	1477	1480	was
O	1481	1491	considered
O	1492	1494	to
O	1495	1497	be
O	1498	1502	more
O	1503	1512	difficult
O	1513	1515	to
O	1516	1521	apply
O	1521	1522	,
O	1523	1526	but
B-outcome	1527	1531	self
I-outcome	1531	1532	-
I-outcome	1532	1540	assessed
I-outcome	1541	1553	satisfaction
O	1554	1557	was
O	1558	1565	greater
O	1565	1566	.

O	1567	1571	Body
O	1572	1576	mass
O	1577	1582	index
O	1583	1586	and
O	1587	1595	adjuvant
O	1596	1608	chemotherapy
O	1609	1615	before
O	1616	1628	radiotherapy
O	1629	1634	after
O	1635	1645	lumpectomy
O	1646	1650	were
O	1651	1662	significant
O	1663	1673	prognostic
O	1674	1681	factors
O	1682	1685	for
O	1686	1691	acute
O	1692	1702	dermatitis
O	1702	1703	.

O	1704	1713	Calendula
O	1714	1716	is
O	1717	1723	highly
O	1724	1733	effective
O	1734	1737	for
O	1738	1741	the
O	1742	1752	prevention
O	1753	1755	of
O	1756	1761	acute
O	1762	1772	dermatitis
O	1773	1775	of
O	1776	1781	grade
O	1782	1783	2
O	1784	1786	or
O	1787	1793	higher
O	1794	1797	and
O	1798	1804	should
O	1805	1807	be
O	1808	1816	proposed
O	1817	1820	for
O	1821	1829	patients
O	1830	1840	undergoing
O	1841	1854	postoperative
O	1855	1866	irradiation
O	1867	1870	for
O	1871	1877	breast
O	1878	1884	cancer
O	1884	1885	.
